Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bupropion for Sexual Desire in Women With Breast or Gynecologic Cancer
NCT03180294Phase 2Completed
- Sponsor
- NRG Oncology
- Start
- May 2017
- Primary completion
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of bupropion in Hypoactive Sexual Desire Disorder (HSDD), sponsored by NRG Oncology. Started May 2017; status: completed.
02
Drugs
bupropion
03
Conditions
Hypoactive Sexual Desire Disorder (HSDD)
Beyond the preview
Go deeper on NCT03180294.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03180294.